Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
One Year After the $19 Billion Crypto Crash: Lessons on Leverage

One Year After the $19 Billion Crypto Crash: Lessons on Leverage

CoinEditionCoinEdition2026/10/10 12:15
By:CoinEdition

One year after the October 10, 2025, crypto crash, traders continue to face the lessons of the largest liquidation event in crypto history. The crash wiped out more than $19 billion in leveraged positions and affected over 1.6 million traders.

According to CoinGlass data, approximately $19.1 billion in crypto positions were liquidated between October 10 and 11. Most of the losses came from traders who had bet on prices rising.

The crash began after U.S. President Donald Trump announced an additional 100% tariff on Chinese imports and threatened new export controls. The announcement intensified fears of an escalating trade conflict and triggered widespread selling in financial markets.

Bitcoin, which had recently reached record highs above $126,000, plunged. Its price fell from above $122,000 to around $102,000.

Ethereum and other major cryptocurrencies also suffered heavy losses. The total crypto market capitalization fell by more than 9% at one point, dropping to around $3.8 trillion. BullTheory estimated that the market lost $800 billion in value within hours.

The rapid sell-off left leveraged traders with little time to respond before exchanges automatically closed their positions.

Leverage allows traders to control larger positions with less capital. While leverage magnifies profits when prices move in the trader’s favor, it also magnifies losses when markets move in the opposite direction.

For example, a trader using 10x leverage controls a $10,000 position with just $1,000 in initial margin. A 10% adverse price movement wipes out that initial margin before fees and other adjustments.

This mechanism played a major role in the October 2025 crash. As crypto prices plunged, traders who had bet on rising prices faced automatic liquidations. Exchanges closed positions to limit further losses, adding selling pressure across the market.

The result was a liquidation cascade: falling prices forced more traders out of their positions, and those forced sales drove prices even lower. 

Meanwhile, the crash also exposed weaknesses in exchange risk controls. During extreme market movements, the number of available buyers and sellers declines, bid-ask spreads widen, and traders struggle to close positions at their expected prices. These conditions intensify losses and accelerate liquidations.

(adsbygoogle = window.adsbygoogle || []).push({});

The October 2025 crash remains a stark warning about the dangers of excessive leverage. The central question is whether crypto markets are better equipped to withstand another major economic shock without triggering a similar wave of liquidations.

Market resilience depends on leverage levels, liquidity, exchange safeguards, and how quickly investors respond to new information. Increased institutional investment does not eliminate these risks.

The crash also demonstrated that crypto markets respond directly to events beyond the industry. Trade disputes, interest-rate changes, and other economic developments trigger sharp price movements, even when the news has little direct connection to blockchain technology.

The lesson for traders is that risk management matters as much as price prediction. Keeping positions small, maintaining sufficient margin, and avoiding excessive leverage reduce liquidation risk during volatile market conditions.

The October 2025 crash does not make another event of the same scale inevitable. It shows, however, how quickly a market sell-off can escalate into a crisis when falling prices, excessive leverage, and low liquidity converge.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs